Kevin J. Blinder, MD
Department of Clinical Ophthalmology and Visual Sciences
The Retina Institute
St. Louis, MO 63144, USA
Dr. Blinder completed medical school at the University of Missouri-Kansas City six-year medical program. He completed a residency at the University of Missouri-Columbia and his vitreo-retinal training at the LSU Eye Center in New Orleans, Louisiana. He returned to the University of Missouri-Columbia to become director of the retina service for four years. He then directed the retina service at the University of Tennessee. In 1999 Dr. Blinder returned to his home town of St. Louis, Missouri to join the Retina Institute and is Clinical Professor of Ophthalmology and Visual Sciences at Washington University School of Medicine.
Dr. Blinder has published over 100 articles in ophthalmologic peer-reviewed journals, along with five book chapters. He has presented at the annual meetings of the American Academy of Ophthalmology, the American Society of Retina Specialist, the Retina Society, the Macula Society and the Association for Research in Vision and Ophthalmology. He has also lectured on various topics at numerous meetings both inside and outside the United States.
Dr. Blinder has received numerous awards, including the Vitreous Society Honor Award, the American Academy of Ophthalmology Achievement Award and Senior Achievement Award, the National Marfan Foundation Heartworks, Hero with a Heart award, and the American Society of Retina Specialists Service award. He has been or is currently an investigator in 30 clinical trials dealing with macular degeneration, diabetic retinopathy, uveitis and AIDS. He serves as a reviewer for Jama Ophthalmology (formally Archives of Ophthalmology), British Journal of Ophthalmology, Ophthalmic Surgery and Lasers, Journal of Retinal and Vitreous Diseases, American Journal of Ophthalmology, Eye, Expert Review of Ophthalmology, Canadian Journal of Ophthalmology, Ophthalmology, and others. He has severed on numerous boards and committees and is a past president of the St. Louis Ophthalmological Society and the American Diabetes Association. Dr. Blinder is a member of the Retina Society, American Society of Retina Specialists, and the Macula Society.
Surgical retina: Macular holes, macular pucker, retinal detachments, vitreous substitutes, traction retinal detachments, vitreous surgery.
Medical retina: Macular holes, puckers, diabetic retinopathy, age-related macular degeneration, myopic degeneration, vein occlusions.
HONORS AND AWARDS
University of Missouri Board of Curators Scholarship 1979-1983
Dean’s List, University of Missouri-Kansas City 1979-1984
University Scholar, University of Missouri-Kansas City 1979-1983
Award for Outstanding Achievement, University of Missouri-Kansas City, 1981, 1983
Member, Honor Society of Phi Kappa Phi
Member, Honor Medical Society of Alpha Omega Alpha
Lange Publishing Scholarship Award 1985
Missouri Ophthalmological Society Outstanding Resident Presentation 1987
ARVO Travel Fellowship, Spring 1989
Teaching Appreciation Award, University of Missouri-Columbia, 1995
Teaching Appreciation Award, University of Tennessee, 1996
Vitreous Society Honor Award, 2001
The American Academy of Ophthalmology Achievement Award, 2002
The American Society of Retinal Specialists Senior Honor Award, 2009
The American Academy of Ophthalmology Senior Achievement Award, 2011
The National Marfan Foundation Heartworks, Hero with a Heart Award, 2012
The American Society of Retina Specialists Service Award, 2012
1. Blinder KJ, Scott W, Lange MP: Abuse of cyanoacrylate in child abuse. Arch Ophthalmol 105:1632-1633, 1987.
2. Blinder KJ, Khan JA, Giangiacomo J, Ide CH: Optociliary veins and visual prognosis after central retinal vein occlusions. Ann Ophthalmol 21:192-197, 1989.
3. Paris CL, Peyman GA, Breen C, Blinder KJ: Neonatal macular hemorrhage. Int Ophthalmol 15:153-155, 1991.
4. Blinder KJ, Peyman GA, Paris CL, Gremillion CM Jr: Submacular scar excision in age-related macular degeneration. Int Ophthalmol 15:215-222, 1991.
5. Paris CL, Peyman GA, Blinder KJ, Erickson P: A new macula lens. Ophthalmic Surg 21:659-660, 1990.
6. Blinder KJ, Peyman GA, Paris CL, Dailey JP, Alturki W, Liu KR, Gremillion CM Jr: Vitreon, a new perfluorocarbon. Br J Ophthalmol 75:240-244, 1991.
7. Paris CL, Peyman GA, Gremillion GM Jr, Blinder KJ: Intravitreal dexamethasone following vitreous surgery. Int Ophthalmol 15:173-174, 1991.
8. Peyman GA, Blinder KJ, Liu KR, Paris CL, Shahsavari M, Dailey JP: Perfluorophenanthrene: A new vitreous substitute. New Frontiers in Ophthalmology. C.Y. Khoo et al, Elsevier Science Publishers B.V., 605-607, 1991.
9. Peyman GA, Paris CL, Blinder KJ, Dailey JP: Surgical treatment of melanomas. New Frontiers in Ophthalmology. C.Y. Khoo et al., Elsevier Science Publishers B.V., 599-601, 1991.
10. Paris CL, Peyman GA, Blinder KJ, Alturki W, Dailey JP, Barron BA: Surgical technique for managing rhegmatogenous retinal detachment following prosthokeratoplasty. Retina 11:301-304, 1991.
11. Peyman GA, Blinder KJ, Paris CL, Alturki W, Nelson N, Desai U: A technique for RPE transplantation for age-related macular degeneration secondary to extensive subfoveal scarring. Ophthalmic Surg 22:102-108, 1991.
12. Peyman GA, Blinder KJ, Paris CL, Alturki W, Federman JL, Liu KR, Clark LC Jr: Vitreon: A new perfluorocarbon vitreous substitute. Afro-Asian J Ophthalmol 10:48-57, 1991.
13. Desai U, Peyman GA, Alturki W, Nelson NC, Blinder KJ, Paris CL: Subretinal neovascular membrane as a complication of transscleral diathermy in pars planitis. Afro-Asian J Ophthalmol 10:32-34, 1991.
14. Peyman GA, Nelson NC Jr, Alturki W, Blinder KJ, Paris CL, Desai UR, Harper CA III: Tissue plasminogen activating factor assisted removal of subretinal hemorrhage. Ophthalmic Surg 22:575-582, 1991.
15. Blinder KJ, Peyman GA, Desai UR, Nelson NC Jr, Alturki W, Paris CL: Vitreon, a short-term vitreoretinal tamponade. Br J Ophthalmol 76:525-528, 1992.
16. Alturki WA, Peyman GA, Paris CL, Blinder KJ, Desai UR, Nelson NC Jr: Posterior relaxing retinotomies: Analysis of anatomic and visual results. Ophthalmic Surg 23:685-688, 1992.
17. Desai UR, Peyman GA, Blinder KJ, Alturki WA, Paris CL, Nelson NC Jr: Orbital extension of sinus lymphoma in AIDS patient. Jpn J Ophthalmol 35:205-214, 1992.
18. Desai UR, Peyman GA, Chen CJ, Nelson NC Jr, Alturki WA, Blinder KJ, Paris CL: Use of perfluoroperhydrophenanthrene in the management of suprachoroidal hemorrhages. Ophthalmol 99:1542-1547, 1992.
19. Paris CL, Blinder KJ: Managing dislocated IOLs. Ophthalmol 99:1347, 1992.
20. Peyman GA, Paris GL, Blinder KJ, Alturki W, Desai U, Nelson NC: Internal choroidectomy of posterior uveal melanomas under a retinal flap. Int Ophthalmol, 16:439-444, 1992.
21. Schulman JA, Peyman GA, Blinder KJ, Alturki WA, Desai UR, Nelson NC Jr: Management of giant retinal tears with perfluoroperhydrophenanthrene (Vitreon). Jpn J Ophthalmol 37:70-77, 1993.
22. Peyman GA, Nelson NC Jr, Blinder KJ, Alturki WA, Desai UR, Paris CL: Autologous transplantation of retinal pigment epithelium (RPE) cells. Afro-Asian J. Ophthalmol. 12:237-244, 1993.
23. Goldstein DE, Blinder KJ, Ide CH, Wilson CH, Wiedmeyer H-M, Little RR, England JD, Eddy M, Hewett JE, Anderson S: Glycemic control and development of retinopathy in Youth-onset insulin-dependent diabetes mellitus: Results of a 12 year longitudinal study. Ophthalmology 100:1125-1132, 1993.
24. Blinder KJ: Diabetes case reports from the field. Missouri Medicine 90:72, 1993.
25. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment and diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM 329:977-986, 1993.
26. Blinder KJ, Peyman GA, Paris CL: Diffuse posterior punctate pigment epitheliopathy. Retina 14:31-35, 1994.
27. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. Arch Ophthalmol. 113:36-51,1995
28. Blinder KJ, Friedman SM, Mames RN: Diabetic iris neovascularization, Am J Ophthalmol 120:393-395, 1995.
29. The Effect of Intensive Diabetes Treatment on the Progression of Diabetic Retinopathy in Insulin-Dependent Diabetes Mellitus. The Diabetes Control and Complications Trial. Ophthalmology 102:647-661, 1995.
30. Desai UR, Blinder KJ, Dennehy PJ: Vitrectomy and juvenile epiretinal membrane. Ophthalmic Surgery & Lasers 27:137-139, 1996.
31. The Vitreon Study Group: Surgical management of traumatic retinal detachment with perfluorocarbon liquid. Int Ophthalmol 20:241-249, 1996.
32. The Vitreon Study Group: The Management of Giant Retinal Tears Using Perfluoroperhydrophenanthrene: A Multicenter Case Series. Ophthalmol 104:1159-1165, 1997.
33. Botelho P, Blinder KJ: Retinitis punctata albescens, an unusual variant. Am J Ophthalmol 128:246-247, 1999.
34. Meyer D, Ge J, Blinder KJ, Sinard J, Xu S: Malignant transformation of an optic disk melanocytoma. Am J Ophthalmol 127:710-714, 1999.
35. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group and Verteporfin In Photodynamic Therapy (VIP) Study Group: Acute Severe Vision Decrease after Photodynamic Therapy with Verteporfin: Case Reports from Three Randomized Clinical Trials. Am J Ophthalmol 137:683-96, 2004.
36. Virata SR, Blinder KJ, Shah GK: Diagnostic and Therapeutic Challenges. Retina 22:92-97, 2002.
37. Rao PK, Shah G, Blinder KJ: Bilateral Macular Hole Formation in a Patient with Retinitis Pigmentosa. Ophthalmic Surg Lasers 33:152-154, 2002.
38. Busquets MA, Shah G, Wickens JC, Callanan D, Blinder KJ, Burgess D, Grand MG, Holekamp NM, Boniuk I, Joseph DP, Thomas MA, Fish E, Bakal J, Hollands H, Sharma S: Ocular Photodynamic Therapy With Verteporfin for CNV Secondary to Ocular Histoplasmosis Syndrome. Retina 23:299-306, 2003.
39. Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Pathologic Myopia: Two –Year Results of a Randomized Clinical Trial—VIP Report No. 3. Ophthalmology 110:667-673, 2003.
40. Sheidow T, Blinder KJ, Holekamp NM, Joseph DP, Shah GK: Outcome Results in Macular Hole Surgery: An Evaluation of Internal Limiting Membrane Peeling With and Without ICG. Ophthalmology 110:1697-1701, 2003.
41. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy Study Groups. Effect of lesion size, visual acuity,
and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol 136.407-418, 2003.
42. Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration. Meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy Study Report No. 4. Retina 24:1-12, 2004.
43. Cooper BA, Shah GK, Sheidow TG, Blinder KJ, Grand MG: Outcome of Macular Hole Surgery in Diabetic Patients with Nonproliferative Retinopathy. Retina 24:360-2, 2004.
44. Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP Report No. 3. Am J Ophthalmol 137:683-96, 2004.
45. Cooper BA, Blinder KJ, Shah GK, Foster W, Leibole M: Femtosecond Laser-Induced Premacular Hemorrhage. Retina 24:812-4, 2004.
46. Cooper BA, Blinder KJ, Shah GK, Boniuk I: Intruding Scleral Sutures 12 Years After Primary Repair. Arch Ophthalmol 122:1238-1239, 2004.
47. Sheidow T, Blinder KJ, Shah GK. Outcome Results in Macular Hole Surgery: An Evaluation of Internal Limiting Membrane Peeling With and Without Indocyanine Green (Letter to the Editor). Ophthalmology 111(7):434, 2004.
48. Bandello F, Blinder K, Bressler NM, Brown AL, Miller JW, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Slakter JS, Soubrane G, Strong HA, Stur M; VIP Report No. 5 Writing Committee. Verteporfin in Photodynamic Therapy: Report no. 5 Ophthalmology. 2004 Nov;111(11):2144.
49.Hariprasad SM, Mieler WE, Shah GK, Blinder KJ, Apte RS, Holekamp NM, Thomas MA, Chi J, Prince RA. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration. Trans Am Ophthalmol Soc 102:149-57, 2004.
50. Blinder KJ, Shah GK, Thomas MA, Holekamp NM, Joseph DP, Grand MG, Sharma S. Surgical removal of peripapillary choroidal neovascularization associated with age-related macular degeneration. Ophthalmic Surg Lasers 36:358-64, 2005.
51. Rosenblatt BJ, Shah GK, Blinder KJ: Photodynamic Therapy with Verteporfin for Peripapillary Choroidal Neovascularization. Retina 25:33-37, 2005.
52. Shah GK, Blinder KJ, Hariprasad SM, Thomas MA, Ryan EH, Bakal J, Sharma S: Photodynamic Therapy for Juxtafoveal Choroidal Neovascularization Due to Ocular Histoplasmosis Syndrome. Retina 25:26-32, 2005.
53. Hariprasad SM, Blinder KJ, Shah GK, Apte RS, Rosenblatt B, Holekamp NM, Thomas MA, Mieler WF, Chi J, Prince RA: Penetration Pharmacokinetics of Topically Administered 0.5% Moxifloxacin Ophthalmic Solution in Human Aqueous and Vitreous. Arch Ophthalmol 123: 39-44, 2005.
54. Shah GK, Rosenblatt BJ, Blinder KJ, Grand MG, Smith M. Triamcinolone-assisted internal limiting membrane peeling. Retina 25:972-5, 2005.
55. Hariprasad SM, Shah GK, Mieler WF, Feiner L, Blinder KJ, Holekamp NM, Gao H, Prince RA. Vitreous and aqueous penetration of orally administered moxifloxacin in humans. Arch Ophthalmol 124:178-82, 2006.
56. Hariprasad SM, Shah GK, Blinder KJ. Short-Term Intraocular Pressure Trends Following Intravitreal Pegaptanib (Macugen) Injection. Am J Ophthalmol 141:200-201, 2006.
57. Dhalla MS, Blinder KJ, Tewari A, Hariprasad SM, Apte RS. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 141:752-4, 2006.
58. Wickens J, Blinder KJ: A Preliminary Benefit-risk Assessment of Verteporfin in Age-Related Macular Degeneration. Drug Safety 29:189-199, 2006.
59. Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined Photodynamic Therapy with Verteporfin and Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration. Retina 26(9):988-993, 2006.
60. Tewari A, Shah GK, Dhalla MS, Blinder KJ: Surface Anesthesia for Office-Based Retinal Procedures. Retina 27:804-5, 2007.
61. Dhalla MS, Fantin A, Blinder KJ, Baka JA. The Macular Automated Photostress Test. Am J Ophthalmol 143(4):596-600, 2007.
62. Schadlu R, Blinder KJ, Shah GK, Holekamp NM, Thomas MA, Grand MG, Engelbrecht NE, Apte RS, Joseph DP, Prasad AG, Smith BT, Sheybani A; Intravitreal Bevacizumab for Choroidal Neovascularization in Ocular Histoplasmosis. Am J Ophthalmol 145:875-878, 2008.
63. Smith BT, Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA. Intravitreal Bevacizumab Combined with Verteporfin Photodynamic Therapy for Choroidal Neovascularization in Age-related Macular Degeneration. Retina 2008;28:675-681.
64. Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC. Reversible Cystoid Macular Edema Secondary to Fingolimod in a Renal Transplant Recipient. Arch Ophthalmol 2008:126(1):140-141.
65. Fintak D, Shah GK, Blinder KJ, Regillo C/D, Pollack J, Heier JS, Hollands H, Sharma S. Incidence of Endophthalmitis Related to Intravitreal Injection of Bevacizumab and Ranibizumab. Retina 28:1395-1399, 2008.
66. DCCT Study Group: Prolonged Effect of Intensive Therapy on the Risk of Retinopathy Complications in Patients with Type 1 Diabetes Mellitus: 10 Years After the Diabetes Control and Complications Trial. Archives of Ophthal 126:1707-1715, 2008.
67. Kaiser PK, Antoszyk A, Bernstein P, Blinder K, et al: Verteporfin PDT for Subfoveal Occult CNV in AMD: Two-Year Results of a Randomized Trial. Curr Med Res Opin 25:1853-1860, 2009.
68. Dayani PN, Blinder KJ, Shah GK, Holekamp NM, Joseph DP, Wilson B, Thomas MA, Grand MG: Surgical Outcome of Scleral Buckling Compared with Scleral Buckling with Vitrectomy for Treatment of Macula-Off Retinal Detachment. Ophthal Surg Lasers and Imaging 40:539-547, 2009.
69. Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proceedings of The National Academy of Sciences, 16:7401-7406, 2010.
70. Sheybani A, Almony A, Blinder KJ, Shah GK: Neovascular age-related macular degeneration and anti-VEGF nonresponders. Expert Review of Ophthalmology, 7:35-41, 2010.
71.Mehta S, Blinder KJ, Shah GK, Kymes SM, Schleif SL, Grand MG: Intravitreal Bevacizumab for the Treatment of Refractory Diabetic Macular Edema. Ophthal Surg Lasers and Imaging 41:323-329, 2010.
72. Mansouri A, Almony A, Shah GK, Blinder KJ, Sharma S: Recurrent Retinal Detachment: Does Initial Treatment Matter? Br J Ophthal 94:1344-1347, 2010.
73. Almony A, Mansouri A, Shah GK, Blinder KJ. Efficacy of Intravitreal Bevacizumab After Unresponsive Treatment with Intravitreal Ranibizumab. Can J Ophthalmol 2010;46:182-5.
74. Mehta S, Blinder KJ: Pars Plana Vitrectomy versus Combined Pars Plana Vitrectomy and Scleral Buckle For Primary Repair of Rhegmatogenous Retinal Detachment. Can J Ophthalmol 2011;46:237-241.
75. Almony A, Nudleman E, Shah GK, Blinder KJ, Eliott DB, Mittra RA, Tewari A: Techniques, rationale, and outcomes of internal limiting membrane peeling. Retina 2012;32:877-891.
76. Blinder KJ: Retinal Update: Update on Vitreoretinal Surgery; Macular Edema: Diagnosis and Treatment. Audio-Digest Ophthalmology, Volume 50, Issue 07, April 7, 2012. ISSN 0271-1281.
77. Diabetic Retinopathy Clinical Research Network: Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 131(3):283-93, 2013.
78. Ramaiya KJ, Blinder KJ, Ciulla T, Cooper B, Shah GK: Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome. Ophthalmic Surg Lasers Imaging Retina 44(1):17-21, 2013.
79. Rao RC, Blinder KJ, Smith BT, Shah GK: Internal limiting membrane peeling for primary rhegmatogenous retinal detachment repair. Ophthalmology 120(5):1102-1103, 2013.
80. Blinder KJ, Liu EM: Tractional Retinal Detachment: 101, for the Innovative Retina Surgical Video Series, ASRS. March 2014
81. Blinder KJ, Ahmad B: Subretinal band excision. Video Series, ASRS. May 2014
82. Ying G, Kim BJ, Maguire MG, Huang J, Daniel E, Jaffe GJ, Grunwald JE, Blinder KJ, Flaxel CJ, Rahhal F, Regillo C, Martin DF for the CATT Research Group: Sustained Visual Loss in the Comparison of Age-Related Macular Degeneration Treatments Trials. JAMA Ophthalmol. Doi:10.1001/jamaophthalmol.2014.1019. Published online May 29, 2014. 132(8):915-21, 2014.
83. Meyer JC, Ahmad BU, Blinder KJ, Shah GK: Laser therapy versus observation for symptomatic retinal artery macroaneurysms. Graefes Arch Clin Exp Ophthalmol DOI 10.1007/s00417-014-2730-3, 2014.
84. Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF; Macula Society CSC Collaborative Study Group, Research, and Education Committee and Website Committee: Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 121(5):1073-8, 2014.
85. Walia HS, Shah GK, Blinder KJ: Characteristics and outcomes of sequential rhegmatogenous retinal detachments. Ophthalmic Surg Lasers Imaging Retina 46(4):445-9, 2015.
86. Ho VY, Blinder KJ: Scleral buckle fragment removal with metal fastener clips. Video Series, ASRS. May 2015.
87. Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M,
Pieramici DJ, Sun JK, Beck RW: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 26;372(13):1193-203, 2015.
88. Meyer JC, Shah GK, Blinder KJ, Waheed NK, Reichel E, Stalmans P, Singer M, Tewari A: Early evolution of the vitreomacular interface and clinical efficacy after ocriplasmin injection for symptomatic vitreomacular adhesion. Ophthalmic Surg Lasers Imaging Retina 46(2):209-16, 2015.
89. Rajagopal R, Shah GK, Blinder KJ, Altaweel M, Eliott D, Wee R, Cooper B, Walia H, Smith B, Joseph DP: Bevacizumab Versus Ranibizumab in the Treatment of Macular Edema Due to Retinal Vein Occlusion: 6-Month Results of the CRAVE Study. Ophthalmic Surg Lasers Imaging Retina 46(8):844-50, 2015.
90. Liu EM, Shah G, Blinder KJ, Smith BT, Thomas MA: Intravitreal Aflibercept for Neovascular AMD: Short-Term Clinical Effects of Intravitreal Aflibercept Injection as a Predictor of Long-Term Results. Surg Lasers Imaging Retina 46(10):1021-7, 2015.
91.Walia HS, Shah GK, Blinder KJ: Treatment of CNV secondary to presumed ocular Histoplasmosis with intravitreal aflibercept 2.0 mg injection. Can J Ophthalmol 51(2):91-96, 2016.
92. Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, Scott LC: Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1) Clinical Ophthalmology, Jan 2017.
93. Chinskey ND, Blinder KJ: Rapid Loss of Vision with the Onset of a White Ring Surrounding the Optic Nerve. JAMA Ophthalmol 135(5);493-494, 2017.
94. Shieh W, Shah GK, Blinder KJ: Coats’ Disease-Related Macular Edema Treated with Combined Aflibercept and Laser Photocoagulation. Case Reports in Ophthalmological Medicine 2017, 1-3.
95. Peralta RM, Blinder KJ: Review of Diabetic Macular Oedema Therapy. European Ophthalmic Review. 2017;119202:108-11.
96. Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network: Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018 Feb 1. doi: 10.1001/jamaophthalmol.2017.6565.
97. Jeroudi AM, Shieh W, Chen Y, Connors DB, Blinder KJ, Shah GK: Topical Anesthesia in 27-Gauge Pars Plana Vitrectomy. Journal of VitreoRetinal Diseases. DOI: 10.1177/2474126418762228, 2018
98. Jumper JM, Dugel PU, Chen S, Blinder KJ, Wait JG: Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2). Clinical Ophthalmology 2018, 12: 621-629.
99. Blinder KJ: Anti-VEGF Treatment in Chronic Persistent Diabetic Macular Oedema. European Ophthalmic Review 12(1):21-3, 2018.
100. Connors D, Shah G, Blinder K, Dang S: Early Versus Delayed Vitrectomy for Nondiabetic Vitreous Hemorrhage. Journal of VitreoRetinal Diseases. 2(2):87-90, 2018.
101. Banda H, Shah GK, Blinder KJ: Applications of Fundus Autofluorescence and Widefield Angiography in Clinical Practice. Accepted to CJO 2018.
102. Blinder KJ: Management of Neovascular Ocular Histoplasmosis: Past and Present. Retina. 2018 Oct 31. doi: 10.1097/IAE.0000000000002352.
103. Bressler NM, Beaulieu WT, Maguire MG, Glassman AR, Blinder KJ, Bressler SB, Gonzalez VH, Jampol LM, Melia M, Sun JK, Wells JA 3rd: Diabetic Retinopathy Clinical Research Network: Early Response to Anti-Vascular Endothelial Growth Factor and Two-Year Outcomes Among Eyes With Diabetic Macular Edema in Protocol T. Am J Ophthalmol. 195:93-100, 2018.